Project Switch: Docetaxel as a potential synthetic control in metastatic non-small cell lung cancer (mNSCLC) trials.

被引：0
|
作者：
Menefee, Michael E. [1 ]
Gong, Yutao [1 ]
Mishra-Kalyani, Pallavi Shruti [1 ]
Sridhara, Rajeshwari [1 ]
Kanapuru, Bindu [1 ]
Blumenthal, Gideon Michael [1 ]
Pazdur, Richard [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9105
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.
    Gong, Yutao
    Kehl, Kenneth L.
    Oxnard, Geoffrey R.
    Khozin, Sean
    Mishra-Kalyani, Pallavi Shruti
    Blumenthal, Gideon Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] COGNITIVE CONCERNS AND PERFORMANCE IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC)
    Eggen, Annemarie
    Richard, Nadine
    Shen, Gerald
    Shultz, David
    Leighl, Natasha
    Liu, Geoffrey
    Sun, Alexander
    Bosma, Ingeborg
    Reyners, Anna
    Jalving, Mathilde
    Rodin, Gary
    Edelstein, Kim
    NEURO-ONCOLOGY, 2019, 21 : 159 - 159
  • [3] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270
  • [4] Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy
    Altini, M.
    Massa, I.
    Balzi, W.
    Gentili, N.
    Foca, F.
    Danesi, V.
    Manunta, S.
    Ejzykowicz, F.
    Chandwani, S.
    Burgio, M.
    Cravero, P.
    Verlicchi, A.
    Bronte, G.
    Crino, L.
    Delmonte, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1065 - S1066
  • [5] Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (MNSCLC) with Brain Metastases Treated with Pembrolizumab
    Sun, L.
    Davis, C.
    Marmarelis, M.
    Singh, A.
    Berman, A.
    Feigenberg, S.
    Levin, W.
    Bauml, J.
    Cohen, R.
    Langer, C.
    Aggarwal, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1131 - S1131
  • [6] Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Rossi, Sabrina
    Finocchiaro, Giovanna
    Toschi, Luca
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
    Robert, Nicholas J.
    Chen, Liwei
    Espirito, Janet L.
    Karhade, Mandar
    Evangelist, Makenzi Colleen
    Neubauer, Marcus A.
    Bullock, Susie A.
    Walberg, Jennifer M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] COUGH, DYSPNEA, CHEST PAIN OR A COMPOSITE? ANALYSIS OF KEY SYMPTOMS IN METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) CLINICAL TRIALS
    Castro, Y.
    Corey-Lisle, P. K.
    Holt, T.
    Mamolo, C.
    VALUE IN HEALTH, 2024, 27 (06) : S260 - S260
  • [9] COST OF IMMUNOTHERAPY TO TREAT LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (MUC) AND METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC)
    Bilir, S. P.
    Munakata, J.
    Yim, Y. M.
    Ogale, S.
    VALUE IN HEALTH, 2017, 20 (05) : A99 - A99
  • [10] Docetaxel in non-small cell lung cancer: a review
    Davies, AM
    Lara, PN
    Mack, PC
    Gandara, DR
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (04) : 553 - 565
12345